Journal of Community Health

, Volume 40, Issue 3, pp 404–408 | Cite as

Differences in HPV Immunization Levels Among Young Adults in Various Regions of the United States

  • Mahbubur Rahman
  • Momin Islam
  • Abbey B. Berenson
Original Paper


HPV vaccine uptake in young adult women in the Southern US has been previously found to be the lowest in the country. In addition, geographic variation with regard to HPV vaccination among young adult men has not been investigated yet. The objective of this study was to use the most recent data to determine if inequality still exists. We used Behavioral Risk Factor Surveillance System 2012 data from 8 states (no data available from Midwest) to examine the geographic variations in weighted proportion of adults who initiated (≥1 dose) and completed (3 doses) the HPV vaccine among 3727 young adults (2014 women and 1713 men) 18–26 years old based on self-reported HPV vaccination and socio-demographic characteristics. The weighted vaccine initiation and completion rates among men were: 6.3 and 1.7 % overall, 8.5 and 2.2 % in the Northeast, 6.7 and 1.6 % in the West, and 4.9 and 1.4 % in the South (p = 0.184 and 0.774). The rates among women were: 40.4 % and 27.4, 58.7 and 45.6 %, 39.0 and 24.8 %, and 30.4 and 17.7 % in the respective regions (p < 0.001 for both). Adjusted multivariable logistic regression showed that women living in the South and West were less likely to initiate and complete the 3-dose HPV vaccine series when compared to those in the Northeast. Despite an increase in HPV vaccine uptake among young adult women in all regions, geographic disparity still exists. Moreover, young adult men had very low HPV vaccine initiation and completion rates throughout the US.


Human papillomavirus (HPV) HPV vaccine Vaccine initiation Vaccine completion Young adults Geographic variation 


Conflict of interest



  1. 1.
    Markowitz, L. E., Dunne, E. F., Saraiya, M., Lawson, H. W., Chesson, H., & Unger, E. R. (2007). Quadrivalent human papillomavirus vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations and Reports, 56, 1–24.Google Scholar
  2. 2.
    Centers for Disease Control and Prevention. (2010). FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendation from the Advisory Committee on Immunization Practices (ACIP). MMWR, 59, 626–629.Google Scholar
  3. 3.
    Garland, S. M., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Harper, D. M., et al. (2007). Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. New England Journal of Medicine, 356, 1928–1943.CrossRefPubMedGoogle Scholar
  4. 4.
    Paavonen, J., Naud, P., Salmeron, J., Wheeler, C. M., Chow, S. N., et al. (2009). Efficacy of human papillomavirus (HPV)-16/18 ASO4-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women. Lancet, 374, 301–314.CrossRefPubMedGoogle Scholar
  5. 5.
    Laz, T. H., Rahman, M., & Berenson, A. B. (2013). Human papillomavirus vaccine uptake among 9–17 year old males in the United States: The National Health Interview Survey, 2010. Human vaccines and immunotherapeutics, 9, 874–878.CrossRefPubMedCentralPubMedGoogle Scholar
  6. 6.
    Giuliano, A. R., Tortolero-Luna, G., Ferrer, E., Burchell, A. N., de Sanjose, S., et al. (2008). Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine, 26(Suppl 10), K17–K28.CrossRefPubMedCentralPubMedGoogle Scholar
  7. 7.
    Lacey, C. J., Lowndes, C. M., & Shah, K. V. (2006). Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine, 24(3), S3/35–S3/41.CrossRefGoogle Scholar
  8. 8.
    Williams, W. W., Lu, P. J., O’Halloran, A., Bridges, C. B., Pilishvili, et al. (2014). Centers for Disease Control and Prevention (CDC). Noninfluenza vaccination coverage among adults-United States, 2012. MMWR Morbidity and Mortality Weekly Report, 63, 95–102.PubMedGoogle Scholar
  9. 9.
    Rahman, M., Laz, T. H., & Berenson, A. B. (2013). Geographic variation in human papillomavirus vaccination uptake among young adult women in the United States during 2008–2010: National Health Interview Survey, 2010. Vaccine, 31, 5495–5499.CrossRefPubMedCentralPubMedGoogle Scholar
  10. 10.
    Mokdad, A. H. (2009). The behavioral risk factors surveillance system: Past, present, and future. Annual Review of Public Health, 30, 43–54.CrossRefPubMedGoogle Scholar
  11. 11.
    Centers for Disease Control and Prevention (CDC). (2012). Behavioral Risk Factor Surveillance System Survey Data. Atlanta, Georgia: US Department of Health and Human Services, Centers for Disease Control and Prevention (also Available at
  12. 12.
    Centers for Disease Control and Prevention (CDC). (2012). Behavioral risk factor surveillance system survey questionnaire. Atlanta, Georgia: Department of Health and Human Services, Centers for Disease Control and Prevention.Google Scholar
  13. 13.
    Watson, M., Saraiya, M., Ahmed, F., Cardinez, C. J., Reichman, M. E., et al. (2008). Using population-based cancer registry data to assess the burden of human papillomavirus-associated cancers in the United States: Overview of methods. Cancer, 113(10 Suppl.), 2841–2854.CrossRefPubMedGoogle Scholar
  14. 14.
    Laz, T. H., Rahman, M., & Berenson, A. B. (2013). Human papillomavirus vaccine uptake among 18- to 26-year-old women in the United States during 2008–2010. Cancer, 119, 1386–1392.CrossRefPubMedCentralPubMedGoogle Scholar
  15. 15.
    Wei, F., Moore, P. C., & Green, A. L. (2013). Geographic variability in human papillomavirus vaccination among US young women. American Journal of Preventive Medicine, 44, 154–157.CrossRefPubMedCentralPubMedGoogle Scholar
  16. 16.
    Price, R. A., Tiro, J. A., Saraiya, M., Meissner, H., & Breen, N. (2011). Use of human papillomavirus vaccines among young adult women in the United States: An analysis of the 2008 National Health Interview Survey. Cancer, 117, 5560–5568.CrossRefPubMedCentralGoogle Scholar
  17. 17.
    Chao, C., Velicer, C., Slezak, J. M., & Jacobsen, S. J. (2010). Correlates for human papillomavirus vaccination of adolescent girls and young women in a managed care organization. American Journal of Epidemiology, 171, 357–367.CrossRefPubMedCentralPubMedGoogle Scholar
  18. 18.
    Renwick, T. (2011). Geographic Adjustments of supplemental poverty measure thresholds: Using the American community survey five-year data on housing costs. US Census Bureau. SEHSD Working Paper Number 2011–21 Available at
  19. 19.
    Conroy, K., Rosenthal, S. L., Zimet, G. D., Jin, Y., Bernstein, D. I., et al. (2009). Human papillomavirus vaccine uptake, predictors of vaccination, and self-reported barriers to vaccination. Journal of women’s health, 18, 1679–1686.CrossRefPubMedGoogle Scholar
  20. 20.
    Jain, N., Euler, G. L., Shefer, A., Lu, P., Yankey, D., et al. (2009). Human papillomavirus (HPV) awareness and vaccination initiation among women in the United States, National Immunization Survey—Adult 2007. Preventive Medicine, 48, 426–431.CrossRefPubMedGoogle Scholar
  21. 21.
    Tylor, L. D., Harriri, S., Sternberg, M., Dunne, E. F., & Markowitz, L. E. (2011). Human papillomavirus vaccine coverage in the United States, National Health and Nutrition Examination Survey, 2007–2008. Preventive Medicine, 52, 398–400.CrossRefGoogle Scholar
  22. 22.
    Schluterman, N. H., Terplan, M., Lydecker, A. D., & Tracy, J. K. (2011). Human papillomavirus (HPV) vaccine uptake and completion at an urban hospital. Vaccine, 29, 3767–3772.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Mahbubur Rahman
    • 1
  • Momin Islam
    • 1
  • Abbey B. Berenson
    • 1
  1. 1.Department of Obstetrics and Gynecology, Center for Interdisciplinary Research in Women’s HealthUniversity of Texas Medical BranchGalvestonUSA

Personalised recommendations